Friday, July 10, 2026

pharma

Gedeon Richter Australia

Gedeon Richter Australia is a pharma organization headquartered in AU. NovaPharmaNews links 1 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and US

North Sydney, AU HQ
27 Employees
TGA registrant Type
Company details
Status
Public
HQ
North Sydney, AU
Employees
27
Programs
1
Drugs
5
Patents
0

Quick answer

Gedeon Richter Australia is a pharma organization headquartered in AU. NovaPharmaNews links 1 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

Company snapshot

At Gedeon Richter Australia our mission is to be genuine, honest, and real towards everyone we meet. We believe in being real in what we do, and understanding people truly helps others along their health journey. We are a pharmaceutical company that offers real health support, education, and treatment, which delivers real benefits. Being real is who we are, how we act and why we’re here. To make a

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Gedeon Richter Australia. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Gedeon Richter Australia.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Gedeon Richter Australia.

  1. Clinical update

    Terrosa 20 micrograms/80 microliters solution... — Approved

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Gedeon Richter Australia?

    Gedeon Richter Australia is a pharma organization headquartered in AU. NovaPharmaNews links 1 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (1).

  • Is Gedeon Richter Australia publicly traded?

    Gedeon Richter Australia appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Gedeon Richter Australia develop or market?

    We link 5 drug profile(s) where Gedeon Richter Australia is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gedeon-richter-ltd#company-drugs.

  • What are the latest developments for Gedeon Richter Australia?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Gedeon Richter Australia focus on?

    No specific therapeutic focus areas are currently identified for Gedeon Richter Australia in our database.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
2